Panitumumab in colorectal cancer

Expert Review of Anticancer Therapy

Volumn 7, Issue 7, 2007, Pages 967-973

  Wainberg, Zev A ^a   Hecht, J Randolph ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

5 fluorouracil; Bevacizumub; Colorectal cancer; Combination chemotherapy; Epidermal growth factor receptor; Irinotecan; Leucovorin; Oxaliplatin; Panitumumab; Transforming growth factor; Vascular endothelial growth fator

Indexed keywords

AMPHIREGULIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIREGULIN; ERLOTINIB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; H R3; IRINOTECAN; MAGNESIUM; MATUZUMAB; MITOGEN ACTIVATED PROTEIN KINASE; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; NIMOTUZUMAB; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VECTIBIX;

ACNE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; HUMAN; HYPOMAGNESEMIA; IMMUNOHISTOCHEMISTRY; INJECTION SITE REACTION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PARONYCHIA; PHARMACODYNAMICS; PROTEIN EXPRESSION; PRURITUS; SALVAGE THERAPY; SKIN FISSURE; SKIN TOXICITY; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; HUMANS;

EID: 34547554385     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.7.967     Document Type: Article

References (32)

1. Real FX, Rettig WJ, Chesa PG, Melamed MR, Old LJ, Mendelsohn J. Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. Cancer Res. 46, 4726-4731, (1986).
2. Yasui W, Sumiyoshi H, Hata J et al. Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res. 48(1), 137-141 (1988).
3. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2(2), 127-137 (2001).
4. Yokoi K, Thaker PH, Yazici S et al. Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. Cancer Res. 65(9), 3716-3725 (2005).
5. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337-345 (2004).
6. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22(7), 1201-1208 (2004).
7. Rougier P, Raoul JL, Van Laethem JL et al. Cetuximab plus FOLFIRI as first-line treatment for metastatic colorectal cancer. J. Clin. Oncol. 22, 3513 (2004).
8. Tabernero JM, Van Cutsem J, Sastre J et al. An international Phase II study of cetuximab in combination with oxaliplatin/5-FU/folinic acid (FOLFOX-4) in the first line treatment of patients with metastatic colorectal cancer expressing EGFR. Proceedings of the 40th Annual Meeting of the American Society of Clinical Oncology. New Orleans, LA, USA, 5-8 June 2004.
9. Erbitux®, Package Insert. ImClone Systems Inc., NJ, USA.
10. Lynch DH, Yang XD. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin. Oncol. 29(1 Suppl. 4), 47-50 (2002).
11. Yang XD, Jia XC, Corvalan J, Wang P, Davis CG, Jakobovits A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 59, 1236-1243 (1999).
12. Foon K, Yang XD, Weiner LM et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int. J. Radiat. Oncol. Biol. Phys. 58, 984-990 (2004).
13. Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K. Antibody-dependent cellular cytotoxicity against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci. DOI 10.1111/j.1349-7006.2007.00510 (2007) (Epub ahead of print).
14. Crawford? J, Sandler AB, Hammond LA et al. ABX-EGF in combination with paclitaxel and carboplatin for advanced non small cell lung cancer. Proceedings of the 40th Annual Meeting of the American Society of Clinical Oncology. New Orleans, LA, USA, 5-8 June 2004.
15. Weiner L. Updated results from a dose and schedule study of panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies. Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA, 13-17 May 2005.
16. Rowinsky EK, Schwartz GH, Gollub JA et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J. Clin. Oncol. 22, 3003-3015 (2004).
17. Malik I, Hecht JR, Patnaik A et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA, 13-17 May 2005.
18. Berlin J, Neubauer M, Swanson P et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥10% epidermal growth factor receptor (EGFr). Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology. Atlanta, GA, USA, 2-6 June 2006.
19. Hecht JR, Mitchell E, Baranda J et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1-9%) or negative (<1%) levels of epidermal growth factor receptor (EGFr). Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology. Atlanta, GA, USA, 2-6 June 2006.
20. Van Cutsem E, Peeters M, Siena S et al. Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 25, 1658-1664 (2007).
21. Saltz L, Lenz H, Kindler HL et al. Interim report of randomized Phase II trial of cetuximab/bevacizumab/irinotecan vs cetuximab/ bevacizumab in irinotecan-refractory colorectal cancer. Proceedings of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Hollywood, FL, USA, 27-29 January 2005 (Abstract 169b).
22. Cohen RB, Falcey JW, Paulter VJ et al. Safety profile of the monoclonal antibody C225 in the treatment of EGFr positive tumors. Proceedings of the 36th Annual meeting of the American Society of Clinical Oncology. New Orleans, LA, USA, 19-23 May 2000 (Abstract 1862).
23. Hecht JR, Peeters M, Van Cutsem E, Berlin J, Visonneau S. Safety and tolerability of panitumumab, a fully human monoclonal antibody (Mab), in patients (Pts) with metastatic colorectal cancer (mCRC). Ann. Oncol. 17(Suppl. 9), 361 (2006).
24. Patel DD, Goldberg RM. Cetuximab-associated infusion reactions: pathology and management. Oncology 20(11), 1373-1382 (2006).
25. Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypomagnesemia. J. Natl Cancer Inst. 97(16), 1221-1224 (2005).
26. Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 23, 1803-1810 (2005).
27. Starling N, Cunningham D. Monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptor in advanced colorectal cancers: present and future directions. Curr. Opin. Oncol. 16(4), 385-390 (2004).
28. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J. Clin. Oncol. 22(23), 4772-4778 (2004).
29. Lievre A, Bachet JB, Ychou M et al. KRAS mutations in colorectal cancer is a predictive factor of response and progression free survival in patients treated with cetuximab. Proceedings of the American Association for Cancer Research Annual Meeting. Los Angeles, CA, USA, 14-18 April 2007.
30. Ford S, Garrett CR, Clark EA et al. Expression of epiregulin and amphiregulin and K-RAS mutation status predicit disease control in metastatic colorectal cancer patients treated with cetuximab. Proceedings of the American Association for Cancer Research Annual Meeting. Los Angeles, CA, USA, 14-18 April 2007.
31. Perez-Soler R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin. Lung Cancer. 8(Suppl. 1), S7-S14 (2006).
32. Van Cutsem E, Humblet Y, Gelderblom H et al. Cetuximab dose-escalation study in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): PK and efficacy data of a randomized study. Proceedings of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Orlando, FL, USA, 19-21 January 2007.